MedTrace Logo

Symptoms Associated with Chemotherapy-Induced Peripheral Neuropathy

NCT06352567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2025-02-19

No results posted yet for this study

Summary

Breast cancer remains the most frequent type of cancer globally. Nevertheless, the increased rate of disease-free survival of breast cancer brought the specific need of managing of short and long-term side effects of multimodal treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating conditions which is characterized by a wide variety of experienceable symptoms by patients that need to be addressed in detail. Therefore, in this cross-sectional study, it was aimed to assess the potential symptoms associated with CIPN of patients with breast cancer who underwent systemic chemotherapy. In addition, it was aimed to assess the potential associations between experienced symptoms of CIPN and sociodemographic (age, body mass index etc.) and clinical features (mean exposed dose, type of surgery (if any) etc.).

Conditions

  • Chemotherapy-induced Peripheral Neuropathy
  • Breast Cancer
  • Breast Cancer Female

Interventions

OTHER

European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire

It consists of a total of 20 items each is scored from "1: not at all" to "4: very much" in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively

Sponsors & Collaborators

  • Izmir Bakircay University

    lead OTHER

Principal Investigators

  • Alper Tuğral, Ph.D. · Izmir Bakircay University

  • Murat Akyol, MD, Prof. · Izmir Bakircay University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-18
Primary Completion
2024-07-01
Completion
2024-08-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06352567 on ClinicalTrials.gov